Immunogenicity in biologic therapy: Implications for dermatology;Inmunogenicidad en terapia biológica. Implicaciones en Dermatología

Actas Dermo-Sifiliograficas

Volumn 104, Issue 6, 2013, Pages 471-479

  Carrascosa, J M ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Antidrug antibodies; Biologic therapy; Drug survival; Immunogenicity; Psoriasis

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; DERMATOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LONG TERM CARE; PSORIASIS; TREATMENT RESPONSE;

EID: 84879460768     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2013.02.003     Document Type: Short Survey

References (35)

1. H. Schellekens Immunogenicity of therapeutic proteins: clinical implications and future prospects Clin Ther 24 2002 1720 1740
2. H. Schellekens The immunogenicity of therapeutic proteins Discov Med 9 2010 560 564
3. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate- to- severe plaque psoriasis J Am Acad Dermatol 56 2007 31e1 31e15
4. M. Lebwohl, N. Yeilding, P. Szapary, Y. Wang, S. Li, and Y. Zhu Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations J Am Acad Dermatol 63 2010 571 579
5. D. Jullien Anticorps anti- médicament, auto- anticorps et traitements biologiques du psoriasis Ann Dermatol Venereol 139 2012 S58 S67
6. P. Schouwenburg, L. van de Stadt, R. de Jong, E. van Buren, S. Kruithof, and E. de Groot Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation Ann Rheum Dis 2012 1 6
7. G.J. Wolbink, L.A. Aarden, and B.A. Dijkmans Dealing with immunogenicity of biologicals: Assessment and clinical relevance Curr Opin Rheumatol 21 2009 211 215
8. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: A comprehensive review Pharmacol Ther 117 2008 244 279
9. S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726
10. L.L. Lecluse, R.J. Driessen, P.I. Spuls, E.M. de Jong, S.O. Stapel, and M.B. van Doorn Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis Arch Dermatol 146 2010 127 132
11. E. Adişen, A. Aral, C. Aybay, and M.A. Gürer Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study J Dermatol 37 2010 708 713
12. Zhu Y, et al. Poster 563. Presented at EADV 19th Annual Congress. Gothenburg: 6-10 October; 2010.
13. C. Plasencia, D. Pascual-Salcedo, L. Nuño, G. Bonilla, A. Villalba, and D. Peiteado Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab Ann Rheum Dis 71 2012 1955 1960
14. K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic, and T. Saxne Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab Arthritis Rheum 54 2006 3782 3789
15. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, C. Guzzo EXPRESS study investigators Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase iii, multicentre, double-blind trial Lancet 366 2005 1367 1374
16. G.M. Bartelds, C.L. Krieckaert, M.T. Nurmohamed, P.A. van Schouwenburg, W.F. Lems, and J.W. Twisk Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up JAMA 305 2011 1460 1468
17. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase iii trial J Am Acad Dermatol 58 2008 106 115
18. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, and N. Yeilding Efficacy and safety of ustekinumab, ahuman interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 52- week results from a randomised, double- blind,placebo- controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
19. C. Leonardi, B. Strober, A.B. Gottlieb, B.E. Elewski, J.P. Ortonne, and P. van de Kerkhof Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study J Drugs Dermatol 9 2010 928 937
20. A. Jamnitski, C.L. Krieckaert, M.T. Nurmohamed, M.H. Hart, B.A. Dijkmans, and L. Aarden Patients non- responding toetanercept obtain lower etanercept concentrations compared with responding patients Ann Rheum Dis 71 2012 88 91
21. Remicade summary of product characteristics 2012. [consultado Dic 2012]. Disponible en: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000240/human-med-001023.jsp consultado diciembre 2012.
22. L.A. Korswagen, G.M. Bartelds, C.L. Krieckaert, F. Turkstra, M.T. Nurmohamed, and D. van Schaardenburg Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study Arthritis Rheum 63 2011 877 883
23. J. Barker, M. Hoffmann, G. Wozel, J.P. Ortonne, H. Zheng, and H. van Hoogstraten Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1) Br J Dermatol 165 2011 1109 1117
24. G.M. Bartelds, C.A. Wijbrandts, M.T. Nurmohamed, S. Stapel, W.F. Lems, and L. Aarden Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis Ann Rheum Dis 66 2007 921 926
25. U. Klotz, A. Teml, and M. Schwab Clinical pharmacokinetics and use of infliximab Clin Pharmacokinet 46 2007 645 660
26. J.P. Ortonne, A. Taïeb, A.D. Ormerod, D. Robertson, J. Foehl, and R. Pedersen Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept Br J Dermatol 161 2009 1190 1195
27. A. Moore, K.B. Gordon, S. Kang, A. Gottlieb, B. Freundlich, and H.A. Xia A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis J Am Acad Dermatol 56 2007 598 603
28. K.B. Gordon, A.B. Gottlieb, C.L. Leonardi, B.E. Elewski, A. Wang, and A. Jahreis Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy J Dermatolog Treat 17 2006 9 17
29. D. Moreno-Ramírez Empleo intermitente y uso racional de fármacos biológicos en la psoriasis Actas Dermosifiliogr 102 2011 241 243
30. A. Jamnitski, G.M. Bartelds, M.T. Nurmohamed, P.A. van Schouwenburg, D. van Schaardenburg, and S.O. Stapel The presence orabsence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept Ann Rheum Dis 70 2011 284 288
31. C.I. Daïen, V. Daïen, E. Parussini, A.M. Dupuy, B. Combe, and J. Morele Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: A pilot study J Rheumatol 39 2012 8 10.3899/jrheum.111522
32. H. Takahashi, H. Tsuji, A. Ishida-Yamamoto, and H. Izukapi Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis J Dermatol Dermatol 39 2012 1 4
33. E. Martín-Mola, C. Plasencia, and A. Balsa Cambio a un segundo anti-TNF cuando ha fracasado el primero (switching) en la artritis reumatoide. ¿Qué nos aportan los nuevos datos sobre inmunogenicidad? Reumatol Clin Supl 6 2011 23 28
34. M.W. Meyer, C. Zachariae, K. Bendtzen, and L. Skov Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors Acta Derm Venereol 92 2012 362 364
35. C.L. Krieckaert, A. Jamnitski, M. Nurmohamed, P. Kostense, M. Boers, and G. Wolbink Comparison of long-term clinical outcome of etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Arthritis Rheum. 64 2012 3850 3855 DOI 10.1002/art.34680